Danilo Galizia

679 total citations
32 papers, 285 citations indexed

About

Danilo Galizia is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Danilo Galizia has authored 32 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Otorhinolaryngology. Recurrent topics in Danilo Galizia's work include Cancer Immunotherapy and Biomarkers (11 papers), Head and Neck Cancer Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Danilo Galizia is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Head and Neck Cancer Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Danilo Galizia collaborates with scholars based in Italy, United States and Switzerland. Danilo Galizia's co-authors include Elena Geuna, Marco Merlano, Filippo Montemurro, Nerina Denaro, Ornella Garrone, Ivana Sarotto, Anna Sapino, Massimo Aglietta, Fiorella Ruatta and Alice Bartolini and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and BMC Cancer.

In The Last Decade

Danilo Galizia

30 papers receiving 282 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Danilo Galizia Italy	10	179	108	68	58	35	32	285
Laura Mansi France	12	228 1.3×	94 0.9×	80 1.2×	85 1.5×	57 1.6×	30	373
Yuxin Chu China	9	136 0.8×	112 1.0×	69 1.0×	71 1.2×	20 0.6×	27	286
Lyudmila Zhukova Russia	7	201 1.1×	122 1.1×	70 1.0×	58 1.0×	38 1.1×	89	287
Takahiro Nakagomi Japan	12	169 0.9×	252 2.3×	168 2.5×	58 1.0×	20 0.6×	31	427
Binliang Liu China	12	228 1.3×	134 1.2×	183 2.7×	134 2.3×	14 0.4×	34	384
Yuichi Ando Japan	9	130 0.7×	76 0.7×	32 0.5×	119 2.1×	32 0.9×	47	301
Amy Sullivan United States	6	258 1.4×	160 1.5×	87 1.3×	110 1.9×	124 3.5×	16	380
Alessandra Ferro Italy	11	183 1.0×	174 1.6×	76 1.1×	79 1.4×	19 0.5×	37	315

Countries citing papers authored by Danilo Galizia

Since Specialization

Citations

This map shows the geographic impact of Danilo Galizia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danilo Galizia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danilo Galizia more than expected).

Fields of papers citing papers by Danilo Galizia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danilo Galizia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danilo Galizia. The network helps show where Danilo Galizia may publish in the future.

Co-authorship network of co-authors of Danilo Galizia

This figure shows the co-authorship network connecting the top 25 collaborators of Danilo Galizia. A scholar is included among the top collaborators of Danilo Galizia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danilo Galizia. Danilo Galizia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Merlano, Marco, Nerina Denaro, Danilo Galizia, et al.. (2025). Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide in head and neck cancer: the CONFRONT phase I-II trial. ESMO Open. 10(4). 104498–104498.

Gurizzan, Cristina, Adriana Alberti, Carlo Resteghini, et al.. (2024). 891P Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer: The POINT study. Annals of Oncology. 35. S633–S633. 1 indexed citations

Galizia, Danilo, Sadatsugu Minei, Ange Polidori, et al.. (2023). 863P Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs) +/- chemotherapy (CT) and prebiotic inulin in the PRINCESS study. Annals of Oncology. 34. S560–S560.

Bramati, Chiara, Lara Valentina Comini, Eliano Cascardi, et al.. (2023). Current evidence on diagnosis and treatment of parotid gland lymphomas: a systematic review. European Archives of Oto-Rhino-Laryngology. 280(12). 5219–5227. 4 indexed citations

Rizzo, Alessio, Alberto Miceli, Manuela Racca, et al.. (2023). Diagnostic Accuracy of [68Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis. Pharmaceuticals. 16(12). 1664–1664. 10 indexed citations

Merlano, Marco, Nerina Denaro, Danilo Galizia, et al.. (2023). Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment. Cancers. 15(21). 5257–5257. 4 indexed citations

Galizia, Danilo, et al.. (2022). How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy. Biomedicines. 10(10). 2498–2498. 14 indexed citations

Merlano, Marco, et al.. (2022). Why Oncologists Should Feel Directly Involved in Persuading Patients with Head and Neck Cancer to Quit Smoking. Oncology. 101(4). 252–256. 4 indexed citations

Michelotti, Andrea, Elena Geuna, Fiorella Ruatta, et al.. (2022). Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression. Vaccines. 10(1). 78–78. 18 indexed citations

10.

Guarini, Vincenzo, et al.. (2021). The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Drug Design Development and Therapy. Volume 15. 2711–2720. 15 indexed citations

11.

Denaro, Nerina, Danilo Galizia, Loretta Gammaitoni, et al.. (2021). P-89 Cytokines behaviour during nivolumab treatment. A subgroup analysis of NIVACTOR study. Oral Oncology. 118. 8–8. 1 indexed citations

12.

Petrelli, Annalisa, Sara E. Bellomo, Ivana Sarotto, et al.. (2020). MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. ESMO Open. 5(5). e000937–e000937. 12 indexed citations

13.

Merlano, Marco, Nerina Denaro, Danilo Galizia, & Ornella Garrone. (2019). How I treat squamous ENT cancer. ESMO Open. 4(Suppl 2). e000542–e000542. 5 indexed citations

14.

Bossi, Paolo, Marco Merlano, Gaetana Rinaldi, et al.. (2019). A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck. Annals of Oncology. 30. v463–v463. 2 indexed citations

15.

Merlano, Marco, Anna Merlotti, Lisa Licitra, et al.. (2018). Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. Clinical and Translational Radiation Oncology. 12. 47–52. 15 indexed citations

16.

Siravegna, Giulia, Elena Geuna, Benedetta Mussolin, et al.. (2017). Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open. 2(4). e000253–e000253. 52 indexed citations

17.

Martinello, Rossella, Sofia Genta, Danilo Galizia, et al.. (2016). New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. Expert Opinion on Pharmacotherapy. 17(16). 2179–2189. 8 indexed citations

18.

Fenocchio, Elisabetta, Ilaria Depetris, Delia Campanella, et al.. (2016). Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. BMC Cancer. 16(1). 793–793. 7 indexed citations

19.

Ruatta, Fiorella, Angela Gernone, Caterina Aversa, et al.. (2016). Prospective evaluation of the cardiovascular safety profile of abiraterone acetate (AA) in mCRPC patients (pts).. Journal of Clinical Oncology. 34(15_suppl). e16534–e16534. 2 indexed citations

20.

Gatti, Marco, Gaetano De Rosa, Antonio Manca, et al.. (2012). Gingival metastasis of a radiotherapy-induced breast angiosarcoma. Anti-Cancer Drugs. 23(10). 1112–1117. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Mansi Breakdown of academic impact, for papers by Yuxin Chu Breakdown of academic impact, for papers by Lyudmila Zhukova Breakdown of academic impact, for papers by Takahiro Nakagomi Breakdown of academic impact, for papers by Binliang Liu Breakdown of academic impact, for papers by Yuichi Ando Breakdown of academic impact, for papers by Amy Sullivan Breakdown of academic impact, for papers by Alessandra Ferro